Found 4 articles for: "Halobetasol Propionate"
Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion With a Ceramide-Containing Moisturizer in Adults With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 50 | Copyright © February 2024
Introduction: Moisturizers are often used as adjuvant therapy for psoriasis to assist with rehydration and skin barrier restoration. Fixed-combination halobetasol propionate 0.01...
Read MoreBreaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene
March 2023 | Volume 22 | Issue 3 | Original Article | 247 | Copyright © March 2023
Topical therapies are commonly used to treat psoriasis, either as monotherapy for milder disease or as adjuncts to systemic and biologic drugs. Topical steroids and tazarotene are both options fo...
Read MoreAn Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis
November 2021 | Volume 20 | Issue 11 | Original Article | 1191 | Copyright © November 2021
Up to 80% of individuals with plaque psoriasis have scalp involvement, which can have a significant impact on the quality of life of affected individuals. Despite advancements in psoriasis therapeutic...
Read MoreFixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%–5% Affected Body Surface Area
August 2021 | Volume 20 | Issue 8 | Original Article | 829 | Copyright © August 2021
Introduction: Patients with psoriasis and low body surface area (BSA) involvement often experience substantially reduced quality of life and may be candidates for topical therapies. F...
Read More
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.